Abstract

Psoriasis is known as a complex disease with interactions between genes, the body's immune system and environmental factors, which is a chronic inflammation characterized by scaly red plaques. Secretome Hypoxic Mesenchymal Stem Cells (S-HypMSCs) contain various components released by MSCs consisting of chemokines, growth factors and anti-inflammatory cytokines, making it possible as a therapeutic option. This study aims to investigate the effect of S-HypMSCs on psoriasis improvement. MSCs were isolated from the umbilical cord of rats, Secretome which could be mixed with cream and applied to the wounds of psoriasis-like animal models at a dose of 100 μL/kgBW in 100 mg cream for group P1 and 200 μL/kgBW in 100 mg cream for group P2. The control group was treated with a cream base. The mRNA expression of AP1S3 was analyzed using quantitative Reverse Transcription-Polymerase Chain Reaction (qRT-PCR). All examinations were assessed on day 14. There was a significant difference in the healthy group against the psoriasis-like group, psoriasis-like treatment 1 and treatment 2 groups. administration of S-HypMSCs at a dose of 100 μL/kgBW in 100 mg cream and a dose of 200 μL/kgBW in 100 mg cream significantly decreased AP1S3 expression in Psoriasis-like male white rats of the Wistar strain. The administration of S-HypMSCs cream at a dose of 100 μL/kgBW in 100 mg cream and a dose of 200 μL/kgBW in 100 mg cream had an effect on decreasing AP1S3 gene expression between treatment groups compared to controls in psoriasis-like male Wistar rats. imiquimod induced.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call